



Smith, A. D. A. C., Tilling, K. M., Nelson, S. M., & Lawlor, D. A. (2015). Live-birth rate associated with repeat in vitro fertilization treatment cycles. *JAMA - Journal of the American Medical Association*, 314(24), 2654-2662. <https://doi.org/10.1001/jama.2015.17296>

Peer reviewed version

Link to published version (if available):
[10.1001/jama.2015.17296](https://doi.org/10.1001/jama.2015.17296)

[Link to publication record in Explore Bristol Research](#)
PDF-document

University of Bristol - Explore Bristol Research

General rights

This document is made available in accordance with publisher policies. Please cite only the published version using the reference above. Full terms of use are available:
<http://www.bristol.ac.uk/red/research-policy/pure/user-guides/ebr-terms/>

1 **Revision 2: 19th November 2015**

2 **Live-birth rate associated with repeat in vitro fertilisation treatment cycles.**

3 Andrew D.A.C. Smith, PhD^{1,2}, Kate Tilling, PhD^{1,2}, Scott M Nelson, PhD^{3*}, Debbie A

4 Lawlor, PhD^{1,2*}

5 ¹ Medical Research Council Integrative Epidemiology Unit at the University of Bristol, UK

6 ² School of Social and Community Medicine, University of Bristol, UK

7 ³ School of Medicine, University of Glasgow, UK

8 * These authors made equal contributions.

9 **Corresponding author:**

DA Lawlor

School of Social and Community Medicine

University of Bristol

Oakfield House, Oakfield Grove

Clifton

Bristol

BS8 1BN

United Kingdom

d.a.lawlor@bristol.ac.uk

+44 (0)117 3310096

10

11 Word count: 3602

12 Tables: 3

13 Figures: 4

14 Supplementary eTables: 9; eFigures: 2

15

16 **Abstract**

17 **Importance:** The likelihood of achieving a live-birth with repeat in-vitro fertilisation (IVF) is
18 unclear, yet treatment is commonly limited to three or four embryo transfers.

19 **Objective:** To determine the live-birth rate per initiated IVF cycle and with repeated cycles.

20 **Design, Setting and Participants:** Prospective study of 156,947 UK women who received
21 257,398 IVF ovarian stimulation cycles between 2003 and 2010 and were followed until June
22 2012.

23 **Main exposure:** IVF, with a cycle defined as an episode of ovarian stimulation and all
24 subsequent separate fresh and frozen embryo transfers.

25 **Main Outcome(s):** Live-birth rate per IVF cycle and the cumulative live-birth rates across all
26 cycles in all women and by age and treatment type. Optimal, prognosis-adjusted and
27 conservative cumulative live-birth rates were estimated, reflecting 0%, 30% and 100% of
28 women discontinuing due to poor prognosis and having a live-birth rate of zero had they
29 continued.

30 **Results:** In all women the live-birth rate for the first cycle was 29.5% (95%CI: 29.3, 29.7).
31 This remained above 20% up to and including the fourth cycle. The cumulative prognosis-
32 adjusted live-birth rate across all cycles continued to increase up to the ninth, with 65.3%
33 (64.8, 65.8) of women achieving a live-birth by the sixth cycle. In women younger than 40
34 using their own oocytes, the live-birth rate for the first cycle was 32.3% (32.0, 32.5), and
35 remained above 20% up to and including the fourth cycle. Six cycles achieved a cumulative
36 prognosis-adjusted live-birth rate of 68.4% (67.8, 68.9). For women aged 40-42, the live-birth
37 rate for the first cycle was 12.3% (95%CI: 11.8, 12.8), with six cycles achieving a cumulative
38 prognosis-adjusted live-birth rate of 31.5% (29.7, 33.3). For women older than 42 years all
39 rates within each cycle were less than 4%. No age differential was observed among women
40 using donor oocytes. Rates were lower in those with untreated male factor infertility

41 compared to those with any other cause, but treatment with either intra-cytoplasmic sperm
42 injection or sperm donation removed this difference.

43 **Conclusions and relevance:** Among women in the UK undergoing IVF, the cumulative
44 prognosis-adjusted live-birth rate after six cycles was 65.3%, with variations by age and
45 treatment type. These findings support the efficacy of extending the number of IVF cycles
46 beyond three or four.

47

48 **Introduction**

49 In-vitro fertilization (IVF) is commonly stopped after three or four unsuccessful embryo
50 transfers,^{1,2} with three unsuccessful transfers labelled ‘repeat implantation failure’.³ This
51 practice has been influenced by a study of 1,328 embryo transfers undertaken twenty-years
52 ago, without use of intra-cytoplasmic sperm injection (ICSI), which reported a decline in
53 live-birth rates after the fourth cycle.⁴ With one exception,⁵ previous studies of cumulative
54 pregnancy or live-birth rates have been relatively small, with limited ability to precisely
55 estimate cumulative success beyond four transfers.^{4,6-9} Previous studies have defined a cycle
56 of IVF as an embryo transfer.⁵⁻⁹ Thus, each initiation of IVF with ovarian stimulation has
57 been treated as several separate cycles whenever there has been a series of repeated embryo
58 transfers. Given the promotion of single embryo transfer and the effective freezing of
59 embryos have increased markedly over the last 10-15 years,¹⁰⁻¹⁵ it has been suggested that
60 IVF success should be calculated as the live-birth rate per initiated ovarian stimulation,
61 including all subsequent separate fresh and frozen embryo transfers.^{5,10-13}

62

63 The aim of this study was to determine the extent to which repeat IVF cycles continue to
64 increase the likelihood of a live-birth, defining an IVF cycle as the initiation of treatment with
65 ovarian stimulation and all resulting separate fresh or frozen embryo transfers; hereafter we
66 use the term “cycle” for this. Specific objectives were to determine: (i) the live-birth rate
67 within each cycle, and the cumulative rate across all cycles; (ii) how these varied by age and
68 treatment types (use of donor oocyte, ICSI or sperm donation); and (iii) the association
69 between oocyte yield in one cycle and live-birth rate in subsequent cycles.

70

71 **Methods**

72 Ethical approval for this study was provided by the UK Human Fertilisation and Embryology
73 Authority (HFEA) who have statutory obligations to prospectively collect information on all
74 assisted reproductive treatment (ART) in the UK. Women provided written consent for this
75 information to be used in analyses, audit and publications. The HFEA provided us with data
76 on all ART events occurring in the UK between 1st January 2003 and 30th June 2012, with
77 linkage of cycles to individual women and data on birth outcomes. Because all UK clinics,
78 whether private or public, must provide information on any patients treated with ART,
79 together with the outcomes of that treatment, to the HFEA, they are able to link cycles to
80 individual women for all UK ART. We chose the 2003 start date in order to obtain a large
81 cohort representative of contemporary treatment, and June 2012 was the latest date for which
82 the HFEA could provide validated data. Because the live-birth outcome data were incomplete
83 for cycles commencing between January 2011 and June 2012 (as many of these cycles were
84 still continuing and births from them could occur after June 2012) we limited our potentially
85 eligible cohort to ovarian stimulation cycles initiated between 1st January 2003 and 31st
86 December 2010, with live-birth outcome data collected up to June 2012.

87

88 We excluded ART that was not IVF or was undertaken for the purpose of storage, donation
89 or surrogacy. We excluded women who had started IVF before 2003. As in other studies,⁵⁻⁹
90 once a live-birth occurred women were censored from further analysis. To reflect clinical
91 practice and allow comparisons with other studies,^{4,5,7,9} we included all embryo transfers,
92 whether the individual transfer was of one or more embryos.

93

94 Live-birth was defined as an infant born alive after 24 weeks gestation surviving more than
95 one month. The World Health Organisation (WHO) define live-birth as a birth showing any
96 sign of life irrespective of gestational age. As in other studies,^{5, 15,16} we modified this to

capture births that were likely to be viable. We defined an IVF cycle as the initiation of ovarian stimulation and all resulting separate fresh or frozen embryo transfers. The live-birth rate within a cycle was defined as the probability of a live-birth from an ovarian stimulation encompassing all subsequent fresh and frozen embryo transfers from that stimulation. Thus, for those embarking on IVF the live-birth rate within one cycle answers the question ‘*What is my chance of a live-birth with one stimulation and retrieval of oocytes followed by as many subsequent separate embryo transfers as possible from that retrieval?*’ The cumulative live-birth rate at a given cycle was defined as the probability of a live-birth from all cycles up to and including that cycle. This answers the question ‘*What is my total chance of a live-birth with repeat ovarian stimulation and oocyte retrievals, together with the subsequent embryo transfers from each cycle, up to a given cycle number?*’.

Information on age, types of treatment (oocyte donation, sperm donation and ICSI), oocyte yield and other couple characteristics were obtained from the HFEA dataset.

Statistical methods

We calculated the live-birth rates within the first and subsequent cycles up to the ninth, as the proportion of cycles resulting in a live-birth, using a normal approximation to construct confidence intervals. We calculated estimates of cumulative live-birth rates using different assumptions of women who discontinue IVF without a live birth (see below), up to the ninth cycle, using the Kaplan-Meier method with Greenwood’s approximation to calculate confidence intervals (see online supplementary material for full details).^{17,18} We used a log-rank test¹⁹ to compare the live-birth rate within each cycle and cumulatively across all cycles. The first set of comparisons was between woman’s age and oocyte source category and the second was between no male cause of infertility and male cause of infertility with and

without treatment by ICSI or sperm donation. We assessed the relationship of oocyte yield in one cycle to live-birth rates in subsequent cycles in women younger than 40 years using their own oocytes, by calculating the within live-birth rate in the first, second, and third cycles by oocytes retrieved in the first cycle, and also calculating the within live-birth rate up to the fifth cycle by oocytes retrieved in the immediately preceding cycle.

Dealing with discontinuation of IVF

Infertile couples discontinue IVF for a number of reasons, with a systematic review of patient perceptions concluding that the commonest reasons were the physical and/or psychological burden of treatment, relationship or personal problems.²⁰ In any study estimating cumulative live-birth rates assumptions have to be made about what the rate in those who discontinue would have been had they continued. To account for this we calculated ‘optimal’ and ‘conservative’ estimates, which have been assessed in previous studies. In addition we calculated a prognostic-adjusted estimate. The optimal estimate, is based on the observed data, and whilst not always explicit in previous publications, this assumes that the cumulative live-birth rate in women who discontinue IVF without a live-birth, if they had continued would be equal to the rate in those who continue to have further cycles.⁵ The conservative estimate assumes those who discontinue IVF would have had a subsequent live-birth rate of zero.⁵ The true rate is thought to lie between these two.⁷ The prognostic-adjusted estimate aims to obtain this more realistic value. It assumes a fixed proportion of those who discontinue do so because of poor prognosis and that the live-birth rate in that proportion would have been zero, whereas for those who discontinue for other reasons, such as inability to pay, emotional distress or (in our dataset) emigration from the UK, it would have been similar to those who continue with treatment.

For the prognosis-adjusted estimate we considered the woman's age at her first cycle and oocyte yield in the previous cycle to be the strongest prognostic factors, because these have been shown to be strongly related to live-birth success.^{5,7,9,21,22} We checked that these were indicators of live-birth and of discontinuation of treatment in our own data, as well as comparing other available characteristics between those who discontinued and continued treatment after one unsuccessful cycle. To obtain age-adjusted and oocyte yield-adjusted estimates we calculated results for each age strata (18-34, 35-37, 38-39, 40-42, 43-44, 45-50, 50+ years) and for each possible oocyte-yield in the previous cycle and then obtained an average, weighted by the numbers within each category in the first cycle. It was not possible to calculate an age-adjusted estimates for the age stratified analyses as there is too little age variation within the age strata. For any analyses that include women using donor oocytes it is not possible to calculate rates adjusted for oocyte yield in the previous cycle as women using donor oocytes will not have an oocyte yield.

The age and previous oocyte yield adjusted results suggested that 3% of those who discontinued IVF did so because of poor prognosis. However, to calculate a prognostic-adjusted cumulative live-birth rate we assumed 30% of those who discontinued did so because of poor prognosis. We chose a value of ten-times that suggested by our data to obtain a conservative prognostic-adjusted estimate. Full details of how these estimates were calculated are provided in online supplementary material.

As the average population live-birth success rate for a single embryo transfer is between 20-30% in high income countries,¹⁰⁻¹³ we considered 20% to be a benchmark for a good live-birth rate within a cycle. All analyses were undertaken in Stata version 13 MP2. Two-sided p-values < 0.05 were considered to provide evidence against the null hypothesis.

172

173 ***Comparison with live-birth rates in those not receiving ART***

174 We used data on pregnancy and pregnancy loss rates from published literature to estimate
175 live-birth rates in women who conceive naturally.²³⁻²⁵⁴ Two prospective cohort studies of
176 couples actively trying to conceive provided age specific pregnancy rates attained within
177 twelve menstrual cycles.^{23,24} Live birth rates were calculated assuming 20% of natural
178 conceptions result in a pregnancy loss.²⁵

179

180 **Results**

181 Following planned exclusions the eligible cohort included 257,665 cycles in 157,475 women.
182 For all analyses we excluded women with missing linkage information or implausible linkage
183 (i.e. first IVF transfer being a frozen embryo transfer without preceding ovarian stimulation).
184 This resulted in an analysis cohort of 257,398 cycles by 156,947 women (more than 99% of
185 the eligible cohort; **Figure 1**). **Table 1** shows the characteristics of the cohort. **eTable 1**
186 shows characteristics by year of treatment. Because of the large sample size there was
187 statistical evidence of differences in all characteristics, but for most these were small and
188 unlikely to be clinically important. For example, median age of the women differed by one-
189 year and median oocyte retrieval differed by one across the study period. Use of ICSI
190 increased by 11%, and transfer of single embryos by 17%, though the live-birth rate increased
191 by just two-percent across the study period.

192

193 **Table 2** shows the live-birth rate within each cycle for the whole cohort. In all women the
194 live-birth rate for the first cycle was 29.5% (95%CI: 29.3, 29.7). The live-birth rate within
195 cycles remained above 20% for each cycle up to and including the fourth. After their first
196 cycle there were 110,614 women (70.5% of the analysis cohort) who did not have a live-

197 birth. Of these, 37,704 (34.1%) discontinued treatment and 72,910 (65.9%) had at least one
198 more cycle. **eTable 2** compares characteristics between these two groups. Although there was
199 statistical evidence of differences for all characteristics the actual differences were small.

201 The cumulative live-birth rate continued to increase up to the ninth cycle, with a cumulative
202 prognosis-adjusted live-birth rate of 65.3% (64.8, 65.8) by the sixth cycle (**Table 2**). The
203 equivalent optimal (78.0% (77.3, 78.8)) and age-adjusted (76.7% (76.0, 77.5)) estimates for
204 six cycles were similar, while the conservative estimate was 46.8% (46.5, 47.0) (**Table 2 and**
205 **eFigure 1**).

207 Results varied by age and oocyte source (**Figure 2, Table 3, eTables 3 and 4**). In women
208 who were younger than 40 years and using their own oocytes (133,379 women, 85% of the
209 cohort), the live-birth rate for the first cycle was 32.3% (32.0, 32.5). This remained above
210 20% up to and including the fourth cycle. The previous cycle oocyte-yield adjusted and
211 optimal estimates were similar. Six cycles achieved cumulative live-birth rates of 68.4%,
212 (67.8, 68.9), 80.3% (79.5 to 81.0) and 50.7% (50.5, 51.0), for the prognostic-adjusted,
213 optimal and conservative estimates, respectively. For women aged 40-42, the live-birth rate
214 for the first cycle was 12.3% (11.8, 12.8), with six cycles achieving a cumulative live-birth
215 rates of 31.5% (29.7, 33.3), 41.5% (38.0, 44.9), and 19.2% (18.5, 19.8) for prognostic-
216 adjusted, optimal and conservative estimates, respectively. For women older than 42 years all
217 rates within each cycle were less than 4% or based on too few live-births to calculate
218 confidence intervals.

220 Use of donor oocytes removed this age differential, as the log-rank test showed no evidence
221 for different cumulative live-birth rates between age categories (**eTable 3**). Irrespective of

age, women using donor oocytes achieved live-birth rates within each cycle of 29.6% or greater for all cycles up to and including the ninth and a cumulative live-birth rate after six cycles of 86.7% (85.2, 88.3), 91.7% (90.3, 93.1) and 75.5% (74.0, 77.1) for the prognostic-adjusted, optimal and conservative estimates, respectively (**eTable 4**).

Live-birth rates varied by male cause infertility and its treatment (**Figure 3 and eTables 5 to 7**). Women whose infertility was due to a male related cause and who were not treated with either ICSI or donor sperm had lower live-birth rates than those with a non-male cause of infertility (**eTables 3 and 5**). Those with a male cause of infertility who were treated with ICSI had cumulative live-birth rates, after six cycles, of 71.3% (70.5, 72.1), 82.2% (81.1, 83.4) and 54.7% (54.3, 55.2) using the prognostic-adjusted, optimal and conservative estimates, respectively (**eTable 6**). Equivalent results for those with male infertility treated with donor sperm were 81.2% (78.6, 83.9), 90.2% (87.2, 93.1) and 65.9% (63.9, 67.9) respectively (**eTable 7**). Live-birth rates in both of these groups were greater than in those with a non-male cause of infertility (**eTables 3 and 8**).

Figure 4 shows the live-birth rate within the first, second and third cycles plotted against the number of oocytes retrieved in the first cycle in women under 40 years of age using their own oocytes. For those in whom no oocytes were retrieved in the first cycle the live-birth rates in the second and third cycles were greater than 20%. The live-birth rates in the first, second and third cycles continued to increase with increasing oocytes retrieved in the first cycle up to around 15 oocytes; thereafter the curves flatten. Plotting the live-birth rate within any cycle against the number of oocytes retrieved in the previous cycle gave a similar pattern (**eFigure 2**).

Using published data²³⁻²⁵ we estimated that the live-birth rate for women conceiving naturally, who had been trying for 12 menstrual cycles, varied between 58% and 74% depending on the woman's age and frequency of intercourse (**eTable 9**). These estimates are based on studies that only included women younger than 40. Similar cumulative live-birth rates were achieved by the fifth or sixth cycle of IVF treatment in women of this age (**Table 3**), though, in these women, five cycles took a median of 2 years (1st, 3rd quartile: 2, 3).

Discussion

To our knowledge this is the first study to have linked fresh and frozen embryo transfers to obtain estimates of live-birth rate within each IVF ovarian stimulation cycle and cumulative live-birth rates across repeated stimulation cycles. Despite a decline in the success rate within each cycle as the number of these increased, the cumulative rate across cycles increased up to the ninth in the whole cohort, those younger than 40 (using their own oocytes) and those using donor oocytes (irrespective of age). They also increased up to the eighth or ninth in women aged 40-42, though for women older than 42 (using their own oocytes) the likelihood of success was low and the cumulative live-birth rate did not appear to clearly increase beyond the fourth or fifth cycle. For those women able to use donor oocytes, age was unrelated to success. In those for whom the cause of infertility was related to a male partner problem, treatment with ICSI or donor sperm made a marked difference in the likelihood of success, with cumulative rates increasing up to the eighth or ninth cycle, whereas without treatment rates were lower than in those with other causes of infertility. In women under 40 years with a low oocyte yield in a previous cycle there was benefit in continuing with further cycles. We also found women under 40 years could achieve cumulative live-birth rates after five or six cycles that were similar to published live-birth rates achieved naturally within 12

menstrual cycles.²³⁻²⁵ It should be noted, however, that, in these women, five cycles took a median of 2 years.

Widespread adoption of single embryo transfer has reduced multiple pregnancies and adverse perinatal outcomes, but has meant that the chance of a live-birth from a single ovarian stimulation cycle is spread across multiple embryo transfers, which we have assessed here. Since this method of assessing IVF success combines all embryo transfer events following an ovulation stimulation into one analysis unit, we were unable to examine the effect of the number of embryos transferred per event. However, this method of assessing IVF success is increasingly recommended.^{5,10-13} Our results show how success rates per embryo transfer event are misleadingly lower, compared with the rate within each ovarian stimulation cycle. Furthermore, we have previously shown, using unlinked data from the same population, that the number of embryos transferred in one event has a relatively modest effect on live-birth rate, with a difference of 9% in women younger than 40 years and 16% in those aged 40 years or older, comparing double to single embryo transfer.¹⁵

Despite the differences in the definition of cumulative success between our study and the previous largest study (from the US), in which cumulative live-birth rates were estimated on the basis of each embryo transfer,⁵ and differences in health systems between the US and UK, both studies found age differences in rates and that these were removed with the use of donor oocytes. In the US study, those with a male cause of infertility had one of the highest cumulative live-birth rates per embryo transfer, but that study did not examine the effect of different treatments (ICSI or sperm donation) and it may be that all of those with male cause infertility in the US receive one of these treatments.

296 The key limitation of all studies looking at cumulative outcomes with repeat IVF is how one
297 treats those who discontinue treatment. As seen in our data, and in previous studies,^{5,7} the
298 extremes of the optimal and conservative estimates often vary markedly, for example in our
299 data the optimal and conservative estimates were 78.0% and 46.8%, respectively, for the
300 whole cohort. This is because of the differences between these two, in what they assume
301 would have been the live-birth rate in those who discontinued IVF, had they continued; for
302 the optimal estimate this is assumed to be the same as those who did continue, whereas the
303 conservative estimate it is assumed to be zero. We examined the likelihood that such
304 discontinuation was due to poor prognosis based on age and previous cycle oocyte retrieval.
305 These analyses suggested approximately 3% of those who discontinued did so because of
306 poor prognosis. This small proportion was because although these two were important
307 predictors of live-birth, few women receiving IVF are older than 40 years (only 15% in our
308 national population cohort) and most women have a high oocyte yield (median 9 per cycle in
309 our cohort). However, to account for other factors, for example pre-treatment reproductive
310 hormone levels, smoking and body mass index (BMI), which have been linked to live-birth
311 success,^{7,22} but that were not available in this study, we assumed a 30% discontinuation due
312 to poor prognosis. Because of the legal requirement for all UK clinicians to provide data on
313 all ART patients, the HFEA were able to link cycles to individual women even if they moved
314 between clinics within the UK. However, treatment abroad would be absent from our data. A
315 European study, conducted 6 years ago, found very few UK couples travelled for ART to 49
316 clinics in six (non-UK) European countries with high rates of cross-border patients.²⁶ We
317 were only able to assess live-birth as an outcome: future studies should also consider
318 potential adverse effects of continued treatment, including ovarian hyper-stimulation
319 syndrome and possible increased risk of preterm birth, low birth weight or congenital
320 anomalies.^{16,27,28}

We acknowledge that for some couples the emotional stress of repeat treatments may be undesirable and the cost of a prolonged treatment course, with several repeat oocyte stimulation cycles, may be unsustainable for health services, insurers or couples. However, we think the potential for success with further cycles should be discussed with couples. A cost-effectiveness analysis is beyond the scope of this study, and the difficulties of undertaking such analyses for IVF, in which decisions related to how one values a new life and whether ‘benefits’ and ‘costs’ for both parents and the child should be included, are well-documented.²⁹ The costs of IVF treatment vary between countries, whether publicly or privately funded, and the treatment type used, but are in the range of \$14,000 (£9,000, €12,000) to \$17,000 (£11,000, €15,000) per cycle.^{1,29,30} These costs exclude assessment prior to starting IVF and are based on transfer of one fresh embryo. Assuming each additional frozen embryo transfer costs \$4000 to \$5000,³⁰ the cost per couple of continuing to six, rather than having just three cycles, could be as much as \$132,000 compared to \$66,000 (assuming one fresh and one frozen transfer per cycle).

Conclusions

Among women in the UK undergoing IVF, the cumulative prognosis-adjusted live-birth rate after six cycles was 65.3%, with variations by age and treatment type. These findings support the efficacy of extending the number of IVF cycles beyond three or four.

ACKNOWLEDGEMENTS

We thank the staff of the HFEA and the contributing UK clinics for these data. All views are those of the authors and not necessarily those of the HFEA.

Funding: ADACS, KT and DAL work in a Unit that receives funding from the UK Medical

Research Council (www.mrc.ac.uk) (MC_UU_12013/5 and MC_UU_12013/9) and DAL receives support from a NIHR Senior Investigator awards (NF-SI-0611-10196). This work is also supported by a grant from the Wellcome Trust (www.wellcome.ac.uk) which pays ADACS' salary (WT094311MA). The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review or approval of the manuscript; and decision to submit the manuscript for publication.

Author contributions: DAL and SMN designed the study, developed the aims and obtained data. All authors contributed to developing the statistical analysis plan. ADACS completed all statistical analyses. DAL and ADACS wrote the first draft of the paper and all authors contributed to interpreting results and making critical comments on subsequent paper drafts. DAL and ADACS had full access to all the data in the study and take responsibility for the integrity of the data and accuracy of the data analysis.

References

- 1 National Institute for Health and Care Excellence (NICE). Fertility: assessment and treatment for people with fertility problems. NICE clinical guideline CG156, February 2013. <http://guidance.nice.org.uk/CG156>.
- 2 Berg Brigham K, Cadier B, Chevreul K. The diversity of regulation and public financing of IVF in Europe and its impact on utilization. *Hum Reprod* 2013; **28**: 666–75.
- 3 Margoloth EJ, Ben-Chetrit A, Gal M, Eldar-Geva T. Investigation and treatment of repeated implantation failure following IVF-ET. *Hum Reprod* 2006;**21**:3036-43

369 4 Fukuda J, Kumagai J, Kodama H, Murata M, Kawamura K, Tanaka T. Upper
370 limit of the number of IVF-ET treatment cycles in different age groups, predicted
371 by cumulative take-home baby rate. *Acta Obstet Gynecol Scand* 2001;**80**:71-3

372 5 Luke B, Brown MB, Wantman E, et al. Cumulative birth rates with linked assisted
373 reproductive technology cycles. *N Engl J Med* 2012; **366**: 2483–91.

374 6 Stern JE, Brown MB, Luke B, et al. Calculating cumulative live-birth rates from
375 linked cycles of assisted reproductive technology (ART): data from the
376 Massachusetts SART CORS. *Fertil Steril* 2010; **94**: 1334–40.

377 7 Malizia BA, Hacker MR, Pernzias AS. Cumulative live-birth rates after in vitro
378 fertilization. *N Engl J Med* 2009; **360**: 236–43.

379 8 Elizur SE, Lerner-Geva L, Levron J, Shulman A, Bider D, Dor J. Cumulative live
380 birth rate following in vitro fertilization: study of 5310 cycles. *Gynecol*
381 *Endocrinol* 2006; **22**: 25–30.

382 9 Sharma V, Allgar V, Rajkhowa M. Factors influencing the cumulative conception
383 rate and discontinuation of in vitro fertilization treatment for infertility. *Fertil*
384 *Steril* 2002; **78**: 40–6.

385 10 Kupka MS, Ferraretti AP, de Mouzon J, et al. Assisted reproductive technology in
386 Europe, 2010: results generated from European registers by ESHRE. *Human*
387 *Reproduction* 2014; **29**: 2099–113.

388 11 CDC, Centres for Disease Control and Prevention. Reproductive health. Assisted
389 reproductive technology. National Summary and Fertility Clinic Reports 2013.
390 <http://www.cdc.gov/art/pdf/2013-report/art-2013-fertility-clinic-report.pdf>.

391 12 Human Fertilisation and Embryology Authority. Fertility Treatment in 2013:
392 Trends and Figures. London: 2015.
393 http://www.hfea.gov.uk/docs/HFEA_Fertility_Trends_and_Figures_2013.pdf

- 394 13 Macalldowie A, Wang YA, Chambers GM, Sullivan EA. Australian Institute of
395 Health and Welfare, Assisted Reproduction Technology in Australia and New
396 Zealand (AIHW) 2012. National Perinatal Statistical Unit and Fertility Society of
397 Australia. Assisted Reproduction Technology Series, 2012.
398 <http://www.aihw.gov.au/publication-detail/?id=10737423259>.
- 399 14 Maheshwari A, Griffiths S, Bhattacharya S. Global variations in the uptake of
400 single embryo transfer. *Hum Reprod Update* 2011;**17**:107-20.
- 401 15 Lawlor DA, Nelson SM. Effect of age on decisions about the numbers of embryos
402 to transfer in assisted conception: a prospective study. *Lancet* 2012; **379**: 521–7.
- 403 16 Nelson SM, Lawlor DA. Predicting live birth, preterm delivery, and low birth
404 weight in infants born from in vitro fertilisation: a prospective study of 144,018
405 treatment cycles. *PLoS Medicine* 2011; **8**: e1000386.
- 406 17 Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. *J*
407 *Amer Statist Assn* 1958; **53**: 457–81.
- 408 18 Greenwood MA. Report on the natural duration of cancer. *Rep Public Health Med*
409 *Subj (Lond)* 1926; **33**: 1–26.
- 410 19 Bland JM, Altman DG. The logrank test. *BMJ* 2004; **328**: 1073.
- 411 20 Gameiro S, Boivin J, Peronace L, Verhaak CM. Why do patients discontinue
412 fertility treatment? A systematic review of reasons and predictors of
413 discontinuation in fertility treatment. *Hum Reprod Update* 2012; **18**: 652-659
- 414 21 Sunkara SK, Khalaf Y, Maheshwari A, Seep P, Coomarasamy A. Association
415 between response to ovarian stimulation and miscarriage following IVF: an
416 analysis of 124 351 IVF pregnancies. *Hum Reprod* 2010; **29**: 1218–24.

417 22 van Loendersloot LL, van Wely M, Limpens J, Bossuyte PM, Repping S, van der
418 Veen F. Predictive factors in in vitro fertilisation (IVF): a systematic review and
419 meta-analysis. *Hum Reprod Update* 2010; **16**: 577-89.

420 23 Dunson DB, Baird DD, Colombo B. Increased infertility with age in men and
421 women. *Obstet Gynecol* 2004; **103**: 51-56.

422 24 Rothman KJ, Wise LA, Sorensen HT, Riis AH, Mikkelsen EM, Hatch EE.
423 Volitional determinants and age-related decline in fecundability: a general
424 population prospective cohort study in Denmark. *Fertil Steril* 2013; **99**: 1958-64.

425 25 Savitz DA, Hertz-Picciotto I, Poole C, Olshan AF. Epidemiologic measures of the
426 course and outcome of pregnancy. *Epidemiol Rev* 2002; **24**: 91-101.

427 26 Shenfield F, de Mouzon J, Pennings G, et al. Cross border reproductive care in six
428 European countries. *Hum Reprod* 2010;**25**:1361-68

429 27 Delvinge A, Rozenberg S. Epidemiology and prevention of ovarian
430 hyperstimulation syndrome (OHSS): a review. *Hum Reprod Update* 2002; **8**: 559-
431 77

432 28 Davies MJ, Moore VM, Willson KJ, et al. Reproductive technologies and the risk
433 of birth defects. *N Engl J Med* 2012; **366**: 1803–13.

434 29 ESHRE Capri Working Group, Economic aspects of infertility care: a challenge
435 for researchers and clinicians. *Hum Reprod* 2015;**30**:2243-48.

436 30 The cost of IVF: 4 things I learned while battling infertility. By Jennifer Gerson
437 Uffalussy. [http://www.forbes.com/sites/learnvest/2014/02/06/the-cost-of-ivf-4-](http://www.forbes.com/sites/learnvest/2014/02/06/the-cost-of-ivf-4-things-i-learned-while-battling-infertility/)
438 [things-i-learned-while-battling-infertility/](http://www.forbes.com/sites/learnvest/2014/02/06/the-cost-of-ivf-4-things-i-learned-while-battling-infertility/) Accessed 12th October 2015.

439

Figure descriptive titles and legends

Figure 1: Definition of eligible and analysis cohort

Figure 2: Cumulative live-birth rate across all initiated IVF cycles by age and oocyte source.

The figure shows the prognosis-adjusted estimates of cumulative live-birth rates (i.e. the rate (shown on the y-axis) is the likelihood of a live-birth across all initiated cycles up to and including the numbers on the x-axis), with 95% confidence intervals. These are presented for women in two different age categories at the start of their first IVF treatment cycle (< 40 years and 40-42 years; women in both of these categories used their own oocytes) and also in women who used donor oocytes (these women cover the full age range). Data for women aged over 42 at their first treatment cycle are not shown because rates were so low it would have been difficult to represent them on this same graph (full results for these women are shown in Table 3). The prognostic-adjusted estimate assumes that 30% of those who discontinued IVF did so because of poor prognosis and that the live-birth rate in that 30% would have been zero had they continued. Analyses were completed in 156,947 women undergoing 257,398 cycles. Log-rank tests indicated a difference between the cumulative live-births rates for all groups ($p < 0.001$ for all comparisons).

Figure 3: Cumulative live-birth rate across all initiated IVF cycles by ICSI and sperm donation.

The figure shows the prognosis-adjusted estimates of cumulative live-birth rates (i.e. the rate (shown on the y-axis) is the likelihood of a live-birth across all initiated cycles up to and including the numbers on the x-axis), with 95% confidence intervals. These are shown for couples without a male cause of infertility, couples with a male cause who were not treated with ICSI or sperm donation, those with a male cause who were treated with ICSI and those with a male cause who used sperm donation. The prognostic-adjusted estimate assumes that

30% of those who discontinued IVF did so because of poor prognosis and that the live-birth rate in that 30% would have been zero had they continued. Analyses were completed in 156,947 women undergoing 257,398 cycles. Log-rank tests indicated a difference between the cumulative live-births rates for all groups ($p < 0.001$ for all comparisons).

Figure 4: Live-birth rate within each single IVF treatment cycle by oocyte retrieval in first cycle.

The figure shows the live-birth rate within each individual first, second and third treatment cycle (i.e. for each line the rate on the y-axis is the rate for just that one treatment cycle), against the number of oocytes retrieved in the first treatment cycle (shown on the x-axis). Analyses are in 134,903 women aged less than 40 years and using their own oocytes. Box and whiskers show the central 95% of the distribution of oocytes retrieved in the first cycle, as well as the median and lower and upper quartiles.

Table 1: Characteristics of the analysis cohort of 156,947 women commencing IVF treatment for infertility in the UK in 2003-2010 (with outcomes assessed up to June 2012).

Characteristic	For all cycles combined ^a	For first cycle ^b
Number of women	156,947	156,947
Total number of cycles		
1	93,494 (59.6%)	
2	39,707 (25.3%)	
3	15,507 (9.9%)	
More than 3	8,239 (5.2%)	
Number of cycles	257,398	156,947
Live-births (% per cycle)	70,093 (27.2%)	46,333 (29.5%)
Woman's age (years)		
Median (1st quartile, 3rd quartile)	35 (32, 38)	35 (32, 38)
Duration of infertility (years)		
Median (1st quartile, 3rd quartile)	4 (2, 6)	3 (2, 5)
Missing	11,165 (4.3%)	6,586 (4.0%)
Causes of infertility (non-exclusive)		
Tubal	46,535 (18.1%)	28,181 (18.0%)
Ovulatory	34,473 (13.4%)	21,582 (13.8%)
Endometriosis	15,889 (6.2%)	9,654 (6.1%)
Male cause	105,014 (40.8%)	63,023 (40.2%)
Treated with ICSI	123,009 (47.8%)	68,608 (43.7%)
Treated with sperm donation	8,067 (3.1%)	4,781 (3.05%)
Treated with oocyte donation	7,223 (2.8%)	3,587 (2.3%)
Oocytes retrieved (own)	9 (5, 13)	9 (5, 13)
Median (1st quartile, 3rd quartile)		
Embryo transfer events per cycle		
No embryos transferred	31,738 (12.3%)	20,794 (13.3%)
Fresh embryo transfer only	199,713 (77.6%)	119,462 (76.1%)
Fresh and frozen embryo transfer	25,947 (10.1%)	16,691 (10.6%)
Number of embryo transfer events	257,581	157,043
Number of embryos transferred per embryo transfer event ^c		
1	44,330 (17.2%)	29,942 (19.1%)
2	201,888 (78.4%)	122,483 (78.0%)
3-4	11,363 (4.4%)	4,618 (3.0%)

^a The unit of analysis here is cycle (with results the average across all cycles per woman)

^b As this is just one cycle the unit of analysis is the women at their first treatment cycle

^c As there are a variable number of transfer events per treatment cycle (which includes all subsequent fresh and frozen transfer events) the % is per the number of transfer events (not per cycle)

486 **Table 2: Within initiated treatment cycle live-birth rates and cumulative live-birth rate across all cycles in 156,947 women undergoing**
487 **257,398 cycles of IVF**
488

Cycle number	N Cycles	N live-births	Live-birth rate within each cycle % (95%CI)	Cumulative live-birth across all cycles using different estimates % (95%CI)			
				Optimal estimate ^a	Age adjusted estimate ^b	Prognostic-adjusted estimate ^c	Conservative estimate ^d
1st	156,947	46,333	29.5 (29.3, 29.7)	29.5 (29.3, 29.7)	29.5 (29.3, 29.7)	29.5 (29.3, 29.7)	29.5 (29.3, 29.7)
2nd	63,453	15,825	24.9 (24.6, 25.3)	47.1 (46.8, 47.4)	46.7 (46.4, 47.0)	45.1 (44.9, 45.4)	40.5 (40.3, 40.8)
3rd	23,746	5,358	22.6 (22.0, 23.1)	59.0 (58.7, 59.4)	58.3 (57.9, 58.6)	54.3 (54.0, 54.6)	44.6 (44.4, 44.9)
4th	8,239	1,690	20.5 (19.6, 21.4)	67.4 (67.0, 67.9)	66.4 (66.0, 66.9)	59.8 (59.4, 60.1)	46.1 (45.8, 46.3)
5th	3,012	553	18.4 (17.0, 19.7)	73.4 (72.8, 74.0)	72.2 (71.6, 72.7)	63.1 (62.6, 63.5)	46.6 (46.3, 46.8)
6th	1,162	202	17.4 (15.2, 19.6)	78.0 (77.3, 78.8)	76.7 (76.0, 77.5)	65.3 (64.8, 65.8)	46.8 (46.5, 47.0)
7th	458	79	17.2 (13.8, 20.7)	81.8 (80.8, 82.8)	80.5 (79.5, 81.5)	66.8 (66.2, 67.4)	46.9 (46.7, 47.2)
8th	199	37	18.6 (13.2, 24.0)	85.2 (83.9, 86.5)	83.7 (82.4, 85.0)	68.0 (67.3, 68.7)	46.9 (46.7, 47.2)
9th	83	13	15.7 (7.8, 23.5)	87.5 (85.9, 89.1)	86.3 (84.7, 87.9)	68.7 (68.0, 69.5)	46.9 (46.7, 47.2)

489
490 ^a The optimal estimate assumes that the cumulative live-birth rate in women who discontinue IVF without a live-birth, if they had continued,
491 would have been equal to the rate in women who continued to have further IVF. That is it assumes that 0% of women who discontinued IVF did
492 so because of poor prognosis that would have affected their live-birth success had they continued.
493 ^b The age-adjusted estimate assumes that the cumulative live-birth rate in women who discontinued IVF, if they had continued, would have been
494 equal to the rate in women who were the same age at the start of treatment, and who continued to have further IVF. These results suggested
495 approximately 3% of women who discontinued did so because of poor prognosis and would have had a live-birth rate of zero, had they
496 continued.
497 ^c The prognostic-adjusted estimate assumes that 30% of women who discontinued IVF did so because of poor prognosis and would have had a
498 live-birth rate of zero, had they continued.
499 ^d The conservative estimate assumes that the cumulative live-birth rate in all women who discontinued IVF would have been zero, had they
500 continued. That is it assumes that 100% of women who discontinued did so because of poor prognosis and would have had a live-birth rate of
501 zero, had they continued.
502 Note it is not possible to calculate an oocyte-adjusted estimate for the whole cohort due to the presence of women using donor oocytes.

503 **Table 3: Within initiated treatment cycle live-birth rates and cumulative live-birth rate across all cycles in 153,360 women, undergoing**
504 **250,175 cycles of IVF using their own oocytes, stratified by age at first ovarian stimulation cycle.**
505

Cycle number	N Cycles	N live-births	Live-birth rate within each cycle % (95%CI)	Cumulative live-birth across all cycles using different estimates % (95%CI)			
				Optimal estimate ^a	Previous oocyte yield-adjusted estimate ^b	Prognostic-adjusted estimate ^c	Conservative estimate ^d
Aged less than 40 years							
1st	133,379	43,019	32.3 (32.0, 32.5)	32.3 (32.0, 32.5)	32.3 (32.0, 32.5)	32.3 (32.0, 32.5)	32.3 (32.0, 32.5)
2nd	53,568	14,532	27.1 (26.8, 27.5)	50.6 (50.3, 50.9)	50.7 (50.4, 51.1)	48.7 (48.4, 49.0)	44.3 (44.0, 44.5)
3rd	19,719	4,793	24.3 (23.7, 24.9)	62.6 (62.3, 63.0)	62.7 (62.3, 63.1)	58.0 (57.7, 58.4)	48.6 (48.4, 48.9)
4th	6,641	1,419	21.4 (20.4, 22.4)	70.6 (70.1, 71.1)	70.5 (70.1, 71.0)	63.3 (62.9, 63.7)	50.1 (49.8, 50.3)
5th	2,357	449	19.0 (17.5, 20.6)	76.2 (75.6, 76.8)	76.0 (75.4, 76.6)	66.4 (66.0, 66.9)	50.6 (50.3, 50.8)
6th	882	150	17.0 (14.5, 19.5)	80.3 (79.5, 81.0)	80.1 (79.3, 80.8)	68.4 (67.8, 68.9)	50.7 (50.5, 51.0)
7th	335	58	17.3 (13.3, 21.4)	83.7 (82.7, 84.7)	83.4 (82.4, 84.4)	69.8 (69.1, 70.4)	50.8 (50.5, 51.1)
8th	131	25	19.1 (12.4, 25.8)	86.8 (85.4, 88.2)	86.5 (85.1, 87.9)	70.9 (70.1, 71.6)	50.9 (50.6, 51.1)
9th	51	10	19.6 (8.7, 30.5)	89.4 (87.6, 91.2)	88.8 (87.2, 90.3)	71.6 (70.8, 72.5)	50.9 (50.6, 51.2)
Aged 40 to 42 years							
1st	15,561	1,914	12.3 (11.8, 12.8)	12.3 (11.8, 12.8)	12.3 (11.8, 12.8)	12.3 (11.8, 12.8)	12.3 (11.8, 12.8)
2nd	6,671	671	10.1 (9.3, 10.8)	21.1 (20.3, 21.9)	20.8 (20.0, 21.6)	19.8 (19.1, 20.6)	16.8 (16.3, 17.4)
3rd	2,579	223	8.6 (7.6, 9.7)	27.9 (26.8, 29.1)	27.6 (26.5, 28.7)	24.7 (23.8, 25.6)	18.5 (17.8, 19.1)
4th	884	69	7.8 (6.0, 9.6)	33.6 (31.9, 35.2)	33.0 (31.4, 34.7)	28.0 (26.9, 29.2)	19.0 (18.4, 19.6)
5th	301	16	5.3 (2.8, 7.9)	37.4 (34.8, 39.4)	36.5 (34.3, 38.8)	29.7 (28.3, 31.1)	19.1 (18.5, 19.8)
6th	130	9	6.9 (2.6, 11.3)	41.5 (38.0, 44.9)	40.5 (37.3, 43.8)	31.5 (29.7, 33.3)	19.2 (18.6, 19.8)
7th	60	2	3.3 [†]	43.4 (39.1, 47.7)	42.4 (38.4, 46.3)	32.2 (30.2, 34.2)	19.2 (18.6, 19.9)
8th	36	1	2.8 [†]	45.0 (39.8, 50.1)	43.4 (39.1, 47.6)	32.7 (30.5, 34.9)	19.2 (18.6, 19.9)
9th	20	0	0.0 [†]	45.0 (39.8, 50.1)	43.4 (39.1, 47.6)	32.7 (30.5, 34.9)	19.2 (18.6, 19.9)
Aged more than 42 years							
1st	4,420	164	3.7 (3.2, 4.3)	3.7 (3.2, 4.3)	3.7 (3.2, 4.3)	3.7 (3.2, 4.3)	3.7(3.2, 4.3)
2nd	1,578	52	3.3 (2.4, 4.2)	6.9 (5.9, 7.9)	6.9 (5.9, 7.9)	6.3 (5.4, 7.2)	4.9 (4.3, 5.6)
3rd	509	17	3.3 (1.8, 4.9)	10.0 (8.2, 11.7)	9.8 (8.1, 11.5)	8.3 (7.1, 9.6)	5.4 (4.7, 6.0)

4th	160	2	1.3 [†]	11.1 (8.8, 13.4)	10.1 (8.5, 11.8)	8.9 (7.4, 10.5)	5.5 (4.8, 6.2)
5th	67	3	4.5 [†]	15.1 (10.2, 20.0)	14.2 (10.7, 17.7)	10.7 (8.2, 13.2)	5.5 (4.8, 6.2)
6th	24	0	0.0 [†]	15.1 (10.2, 20.0)	14.2 (10.7, 17.7)	10.7 (8.2, 13.2)	5.6 (4.9, 6.3)
7th	10	2	20.0 [†]	32.1 (10.7, 53.5)	22.3 (14.0, 30.5)	15.9 (8.5, 23.2)	5.6 (4.9, 6.3)
8th	5	0	0.0 [†]	32.1 (10.7, 53.5)	22.3 (14.0, 30.5)	15.9 (8.5, 23.2)	5.6 (4.9, 6.3)
9th	4	0	0.0 [†]	32.1 (10.7, 53.5)	22.3 (14.0, 30.5)	15.9 (8.5, 23.2)	5.6 (4.9, 6.3)

506

507 ^a The optimal estimate assumes that the cumulative live-birth rate in women who discontinue IVF without a live-birth, if they had continued,
508 would have been equal to the rate in women who continued to have further IVF. That is it assumes that 0% of women who discontinued IVF did
509 so because of poor prognosis that would have affected their live-birth success had they continued.


510 ^b The previous oocyte yield-adjusted estimate assumes that the cumulative live-birth rate in women who discontinued IVF, if they had continued,
511 would have been equal to the rate in women who had the same oocyte yield in the immediately previous ovarian stimulation treatment, and who
512 continued to have further IVF. These results suggested approximately 3% of women who discontinued did so because of poor prognosis and
513 would have had a live-birth rate of zero, had they continued.


514 ^c The prognostic-adjusted estimate assumes that 30% of women who discontinued IVF did so because of poor prognosis and would have had a
515 live-birth rate of zero, had they continued.

516 ^d The conservative estimate assumes that the cumulative live-birth rate in all women who discontinued IVF would have been zero, had they
517 continued. That is it assumes that 100% of women who discontinued did so because of poor prognosis and would have had a live-birth rate of
518 zero, had they continued.


519 Note it is not possible to calculate an age-adjusted estimate these age stratified analyses and there is too little age variation within the ages
520 stratified groups to further adjust for age.

521 [†] These are cycles for which there was fewer than six live births and for these standard errors and hence confidence intervals could not be
522 calculated





Number of women									
Own oocytes and age < 40	133,379	53,568	19,719	6,641	2,357	882	335	131	51
Own oocytes and age 40-42	15,561	6,671	2,579	884	301	130	60	36	20
Own oocytes and age > 42	4,420	1,578	509	160	67	24	10	5	4
Donor oocytes, all ages	3,587	1,636	939	554	287	126	53	27	8



Number of women		Cycle number									
	No male cause	93,924	37,161	13,645	4,680	1,765	690	277	119	51	
	Male cause, partner sperm, no ICSI	12,536	4,207	1,478	471	148	70	30	15	3	
	Male cause, partner sperm and ICSI	48,016	21,006	8,203	2,911	1,015	377	141	57	24	
	Male cause, donor sperm	2,471	1,079	420	177	84	25	10	8	5	

